Endothelial diaphragms are subcellular structures critical for mammalian survival with poorly understood biogenesis. Plasmalemma vesicle associated protein (PLVAP) is the only known diaphragm component and is necessary for diaphragm formation.
capillaries results in protein losing enteropathy, hypoproteinemia and hypertriglyceridemia causing a kwashiorkor-like wasting syndrome and death. 3, 6 Interestingly, PLVAP reconstitution in the endothelial compartment in mice restores diaphragms exclusively in EC in vascular beds where the diaphragms are native, demonstrating that additional factors are required for diaphragm formation. 3 Very little is known on PLVAP and diaphragm regulation despite their importance. Phorbol esters such as phorbol myristate acetate (PMA) are known to induce robust de novo formation of fenestrae and transendothelial channels with their associated diaphragms in primary EC in culture. 18 PMA also induces diaphragms of caveolae and PLVAP expression in MEK1-dependent and PKC-independent manner. 16 Of note, PMA is also a known secretagogue in human EC. 19 Vascular endothelial growth factor-A (VEGF-A) was also shown to be essential for formation and maintenance of fenestrae with dia-
phragms. VEGF-A (and not FGF-2 or VEGF-C) induces new vessels
with fenestrae with diaphragms [20] [21] [22] [23] [24] [25] in Rac1 dependent manner. 22 Deletion of VEGF-A in the kidney podocytes, pancreas epithelial cells or hepatocytes [26] [27] [28] or systemically delivered VEGFR2 inhibitors 29 result in loss of fenestrae in mice. While overwhelmingly clear in the case of fenestrae, the effect of VEGF-A/VEGFR2 signalling on PLVAP expression modulation seems to be context dependent.
While a VEGFR2 receptor-selective engineered form of VEGF-A upregulates PLVAP expression in single donor human umbilical vein EC (HUVEC), 30 primary EC cultured in presence of VEGF-A do not or poorly express PLVAP 16 and VEGF-A has no effect 17 or even decreases 31 PLVAP expression in immortalized mouse EC lines that constitutively express PLVAP. Moreover, VEGFR2 signalling inhibition in vivo does not modify PLVAP expression in the lung. 32 Finally, the downregulation of PLVAP in specialized vascular beds forming the blood-brain barrier, [33] [34] [35] [36] or in developing arteries, glomeruli and cell culture [37] [38] [39] [40] appear to be controlled by the Wnt and Notch signalling pathways respectively.
In order to arrive at a cell culture system where fenestrae with diaphragms and PLVAP could be induced at high frequency by physiological cues in primary EC, we have sought to dissect the molecular mechanism of PLVAP upregulation by PMA. We show that PMA upregulation of PLVAP mRNA and protein depends on de novo protein synthesis and secretion of a group of proteins that act synergistically in autocrine fashion. Among these secreted proteins, we identified VEGF-A signalling through VEGFR2 as important but not sufficient for PLVAP expression. In addition, we show that PLVAP upregulation by the PMA-induced secreted factors is MEK1-dependent and JNK-, p38-, PI3K-and Akt-independent.
| MATERIALS AND METHODS

| Materials
Recombinant human VEGF-A was from R&D Systems (Minneapolis, MN) (cat#293-VE) or PreproTech (Rocky Hill, NJ), (cat#100-20);
Heparin-Sepharose beads from GE Healthcare (Piscataway, NJ); PMA (cat# P8139) and cycloheximide (CHX) (cat# C4859) from Sigma (St.
Louis, MO); pharmacological inhibitors, see Table 1 , from EMD Calbiochem (San Diego, CA) or SelleckChem (Houston, TX). All general reagents were from Thermo-Fisher (Pittsburgh, PA), unless otherwise stated.
| Antibodies
We used anti-human PLVAP mAb (clone PAL-E) 6 and chicken antihuman PLVAP-C pAb 41 ; mouse anti-GAPDH (clone 1E6D9, cat#60004-1-Ig, Proteintech, Rosemont, IL), mouse anti-ACTB mAb (clone AC40; Sigma); rabbit anti-human VEGF (clone 500-P10, 
| PMA treatments
Endothelial cells were seeded at 50%-80% confluence in 1% gelatin (Sigma, cat# G9391)-coated culture plates and grown to near confluence for 24-48 hours in the manufacturer recommended growth media. Unless otherwise noted, EC were rinsed, and serum starved (2 hours, 37°C, 5%CO2) in EC basal medium (EBM2 or ECBM-2)
prior to PMA treatment.
points, supernatant and cells were harvested and further processed for protein or RNA analysis.
| Protein synthesis inhibition with cycloheximide
For chronic PMA and for conditioned medium (CM) treatments, EC were seeded in duplicate on gelatin-coated plates, grown to near confluence, serum starved 1.5 hours in EBM2 and 30 minutes presence of 10 μg/mL CHX in EBM-BSA and stimulated for the duration of the experiment with 50 nmol/L PMA + 10 μg/mL CHX or with 4-6 hours CM + 10 μg/mL CHX. For pulsed PMA treatment, the difference was that EC were stimulated with PMA/CHX for only 30 minutes followed by chase in EBM-FBS containing 10 μg/mL CHX. At indicated time points, cells were rinsed twice in DPBS and lysed for RNA or protein analysis. 
| Conditioned medium treatments
| Heparin depletion of conditioned medium
Conditioned medium peaks (4-6 and 6-8 hours) were collected from donor cells cultured in six well plates. For each peak the respective CM was pooled in a 15 mL tube and split into two halves. One half was left untreated (control), the other half of the volume was added to 1 mL settled gel of heparin-agarose previously equilibrated (3×, 5 minutes, RT) in EBM-BSA. The mixture was further incubated (1 hour, RT) with gentle end-over-end rotation before the beads were pelleted by centrifugation (600 g, 10 minutes, RT). Two mL per well control CM or heparin-depleted T A B L E 1 Pharmacological inhibitors used in the study Name Concentration used Target selectivity (IC50 in cell-free assays) Other known targets VEGFR inhibitors
PDGFRβ and c-Kit
(100 nmol/L) C2β, hVPS34, DNA-PK and mTOR 
| Heat inactivation of CM
Conditioned medium "peaks" were collected after PMA treatment and split into two equal volumes: one half was heat inactivated (45 minutes, 60°C followed by 2 minutes on ice) and the other one left untreated (control) before transfer to serum starved acceptor cells.
| Pertussis toxin treatment
Acceptor cells were serum starved and then treated for 24 hours with CM in presence or absence of 0.1 μg/mL pertussis toxin (PT) (Sigma, cat# P7208).
| CM fractionation by ultracentrifugation
Conditioned medium "peaks" (4-6 hours) were collected and subjected to ultracentrifugation (1 hour, 100 000 g, 4°C 
| Multiplex cytokine assays
Cytokines were measured in CM using Bio-Plex human cytokine multiplex kits (Bio-Rad, Hercules, CA) by DartLab core facility at Dartmouth.
| RNA isolation
Total RNA was isolated using RNAeasy mini kit (Qiagen, Germantown, MD) or Quick RNA Mini-prep Kit (Zymo Research, Irvine, CA), as per manufacturer's instructions. RNA integrity and quality were determined using Bioanalyzer (Agilent, Santa Clara, CA) and NanoDrop (Thermo-Fisher). RNA preps with A260/280 ratios ranging from 1.97 to 2.02 were used.
| Real-time quantitative PCR
Quantitative real-time PCR was done as before. 15 Briefly, 2 μg of total RNA was reverse transcribed using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA).
Real-time PCR employing TaqMan Gene Expression Master Mix and
Gene For multiplex quantitative real time PCR, reverse transcription was performed on 200 ng RNA using QuantiNova Kit (Qiagen).
Triplex qPCR was performed in duplicate using Luna Universal Probe qPCR Master Mix (New England Biolabs, Ipswich, MA) to determine levels of PLVAP, VEGF, VEGFR1 and VEGFR2 mRNA (Table 2) . Human beta-2-microglobulin (B2M) was used as a housekeeping gene. PCR was run on BioRad CFX96 thermal cycler performed with the following conditions: cycle #1-step 1 95°C for 10 minutes; cycles #2-40-step 1: 95°C for 15 seconds, step 2:
60°C for 1 minute.
Gene expression was quantitated performed with both absolute and relative methods, as described. 42 For absolute quantification, the PCR signal of each gene was compared to the signal obtained using standard curves generated using five 10-fold serial dilutions (100 000 to 10 copies) of constructs containing the gene expression assay target sequence cloned into the pGEM-T vector (Promega, Madison, WI). For each gene, the copy number × Ct (threshold cycle) was plotted and the curve used to calculate the copy number in each sample. In addition, fold difference over the non-treated control (NTC) was calculated as follows: FD (fold difference) = 2 −ΔΔCt in which ΔΔCt = ΔCt−(4 hours NTC ΔCt) and ΔCt = (target RNA Ct)−(calibrator Ct) where calibrator was either ACTB or B2M.
| RT-PCR for VEGFA isoforms
Total RNA (200 ng) from control and PMA treated HDMVECn was reverse transcribed and human VEGF-A isoforms were amplified using forward (5′-TGCGGATCAAACCTCACCAA-3′) and reverse (5′-CCTCCGGACCCAAAGTGCT-3′) primers located in exons 4 and 8b of the human VEGF-A gene, respectively. Primer sequences and PCR amplification conditions were as described. 43 The expected PCR amplicon sizes were: 319 nucleotides for VEGF-A-121 (NCBI transcript NM_001025370.2), 451 nucleotides for VEGF-A-165 (NCBI transcript NM_001025368.2), 523 nucleotides for VEGF-A-189
(NCBI transcript NM_001171624.1).
2.14 | Western blotting 
| Statistics
Data were analysed using Student's t test. P < 0.05 was taken as the level of significance.
3 | RESULTS
| Upregulation of PLVAP mRNA by PMA requires protein translation
In a first step, we asked whether PMA-induced PLVAP mRNA transcription depended on de novo protein synthesis. To answer this, we treated primary human HDMVECn with 50 nmol/L PMA (concentration demonstrated to up-regulate PLVAP and induce the formation of endothelial diaphragms and fenestrae 16 ) in presence or absence of CHX, a protein synthesis inhibitor. 44 As shown previously, 16 cells were exposed to PMA for the entire duration of the experiment.
PLVAP ****mRNA significantly increased in time-dependent manner starting at~2 hours after PMA treatment onset ( Figure 1A ). However, there was no increase of PLVAP mRNA or protein ( Figure 1B) when cells were treated with PMA in presence CHX for up to 8 hours of treatment, demonstrating that PLVAP upregulation by PMA requires de novo protein synthesis.
| PLVAP is up-regulated by PMA-induced soluble proteins
We next asked whether the newly synthesized proteins needed to be secreted and possibly acted in autocrine fashion. First, we
showed that a 30-minute pulse of 50 nmol/L PMA followed by its removal and chase using a defined medium elicits similar levels of A more refined analysis in which donor EC were pulsed with PMA, chased in EBM-FBS and 1 hours CM "peaks" were collected and incubated with naive acceptor EC for 24 hours ( Figure 3C ), showed that the CM collected between 5 and 6 hours post-PMA was able to induce a robust upregulation of PLVAP in naive EC, while other time points had minimal effect ( Figure 3D ). Across multiple experiments carried out with different EC, the highest PLVAP-inducing "activity"
was always found in the CM peaks collected between 4 and 8 hours.
However, 4-6 hours CM was usually more potent than 6-8 hours CM in upregulating PLVAP. Endothelial cells produce chemokines, secreted factors that can bind heparin. 45 We therefore tested the ability of 4-6 and 6-8 hours CM peaks to up-regulate PLVAP in presence of PT, a general/broad | 925 spectrum chemokine receptor inhibitor 46, 47 (schematized in Figure 4C , left). Treatment of acceptor EC with PT had no effect on PLVAP protein upregulation by the 4-6 and 6-8 hours CM peaks ( Figure 4C , right), ruling out a role for chemokine signalling in this system.
| PMA up-regulates PLVAP in part via VEGF/ VEGFR2 signalling
Phorbol myristate acetate up-regulates VEGF-A a known heparinbinding growth factor 48 and its receptors, VEGFR1 and VEGFR2 in HUVEC and HDMVEC, 49 making it them as good candidates for PLVAP upregulation by PMA in EC.
As seen in Figure 5A 3.6 | PMA up-regulates PLVAP in MEK1/2-dependent and p38-, JNK-and PI3K/Akt-independent manner
We next explored the role of signalling pathways downstream of VEGFR2 using pharmacological inhibition ( Table 1 ). The ability of both PMA ( Figure 6E ) and 4-6 hours CM ( Heparin depletion experiments demonstrated that multiple factors in the CM may be involved in PLVAP upregulation by PMA with most but not all of these factors bind heparin.
We were able to rule out a role for chemokines, known to bind heparin, as PT was unable to inhibit PLVAP upregulation by the 4-6 and 6-8 hours CM at a dose widely accepted in the literature as effective.
Among the PMA-induced growth factors known to bind heparin, a survey of the literature yielded VEGF-A as a candidate. VEGF-A signalling via VEGFR2 up-regulates PLVAP in single donor HUVEC. ).
Unfortunately, due to the rather inefficient upregulation of PLVAP by VEGF-A in our cells we were unable to reliably investigate the effect of these inhibitors on PLVAP upregulation by VEGF-A. In any case, the Erk1/2 downstream effectors involved in PLVAP upregulation would be interesting to elucidate in the future.
Plasmalemma vesicle associated protein has also been shown to be regulated by VEGF-A/VEGFR2 signalling in p38 MAPK-dependent manner although no known downstream targets of p38 were found to be involved. 30 Quantitative mRNA analysis (data not shown) demonstrated that HDMVECn express all the p38 isoforms (p38α/ MAPK14, p38β/MAPK11, p38γ/MAPK12, p38δ/MAPK13), with p38γ/ MAPK12 being the least abundant. Nevertheless, our results show no inhibition of PLVAP mRNA upregulation at 8 and 24 hours post either PMA or CM treatment by two widely used pan p38 inhibitors, despite our demonstration that the same doses of these inhibitors block p38 MAPK phosphorylation in response to PMA. Both inhibitors are active against all p38 isoforms with IC50 in the nanomolar range and the doses used were 2-3 orders of magnitude larger.
However, while our data do not support a role for p38 signalling in PMA or CM induced PLVAP upregulation, these results are puzzling given the role of VEGF/VEGFR2 signalling in this process.
Others have suggested that VEGF-A regulates PLVAP expression in PI3 kinase-dependent manner. 30 HDMVEC express all four isoforms of p110 (α/PIK3CA, β/PIK3CB, γ/PIK3CG and δ/PIK3CD) and the respective p85/p55/p150 regulatory subunits (PIK3R1-4). Using novel and more selective PI3K pharmacological inhibitors that are in clinical trials such as pictisilib (highly selective for PI3Kα/δ and 11-25
fold lower selectivity on PI3Kβ/γ) and idelalisib (selective for PI3Kγ>δ), we show that PI3K inhibition does not inhibit PLVAP upregulation by PMA or CM. Accordingly, the inhibition of Akt1-3, a major downstream target of PI3K, does not impact PLVAP upregulation. To note, wortmannin, a pan PI3K inhibitor, is partially effective at the larger concentration of 10 μmol/L either suggesting off-target effects or a role for p110β, which is not covered as well by the other inhibitors used. However, the latter is less likely as the dose of pictisilib we used is several orders of magnitude larger than the IC50 for p110β.
In summary, we find that PLVAP upregulation by PMA requires de novo synthesis of multiple secreted proteins that act in an autocrine manner. One of the soluble factors involved is VEGF-A acting through VEGFR2. The signalling is dependent on MEK1/ERK1/2 and independent of p38, JNK, PI3K and Akt1-3. Further transcriptomic and proteomic studies should identify the factors (or combinations thereof) contributing to PLVAP regulation.
